Abstract
Therapeutic strategies with anti-PD-(L)1 antibodies are now well established in patients with nonsmall-cell lung cancer (NSCLC) without oncogenic addiction. The benefit of immunotherapy, sometimes leading to healing, remains restricted to “hot” tumors characterized by an inflammatory tumor micro-environment. Consequently, there is a need to develop new therapeutics improving the cytotoxic T cell activity. Antibodies targeting co-stimulatory or co-inhibitory receptors are evaluated in combination with anti-PD-(L)1 antibodies. Other approaches include anti-cancer vaccines or oncolytic virus. Overall, the goal is to effectively redirected the immune system against the tumor. This could be achieved and optimized by the identification of predictive biomarkers specific to the tumor and the patient for new individual therapeutic proposals.1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
